This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Lipid lowering agents, cognitive decline, and dementia: the three-city study


Ancelin, Marie-Laure, Carrière, Isabelle, Barberger-Gateau, Pascale, Auriacombe, Sophie, Rouaud, Olivier, Fourlanos, Spiros, Berr, Claudine, Dupuy, Anne-Marie, Ritchie, Karen


Journal Of Alzheimer's Disease: JAD, Volume: 30, No.: 3, Pages.: 629-637

Year of Publication



The aim of this prospective cohort study was to evaluate the effects of lipid lowering agent (LLA) intake on cognitive function in 6,830 community-dwelling elderly persons. Cognitive performance (global cognitive functioning, visual memory, verbal fluency, psychomotor speed, and executive function), clinical diagnosis of dementia, and fibrate and statin use, were evaluated at baseline, and 2, 4, and 7 year follow-up. Multivariate Cox models were stratified by gender and adjusted for sociodemographic characteristics, mental and physical health including vascular risk factors, and genetic vulnerability (apolipoprotein E and cholesteryl ester transfer protein). For women but not men, fibrate use was specifically associated with an increased risk over 7 years of decline in visual memory only (HR = 1.29, 95% CI = 1.09-1.54, p = 0.004), and did not increase risk for incident dementia. This association was independent of genetic vulnerability related to apolipoprotein E and cholesteryl exchange transfer protein polymorphisms and occurred only in women with higher low density lipoprotein (LDL)-cholesterol levels and treated with fibrate (HR = 1.39, 95% CI = 1.08-1.79, p = 0.01) and not in those with lower LDL-cholesterol levels irrespective of fibrate treatment. For both genders, no significant associations were found between statins (irrespective of their lipophilicity) and either cognitive decline or dementia incidence. This prospective study, adjusting for multiple confounders, found no evidence that LLA given in late life reduced the risk of cognitive decline and dementia, but did raise the possibility that women with treatment-resistant high LDL-cholesterol may be at increased risk of decline in visual memory.;


aged, aged, 80 and over, agent, apolipoproteins e, cognition, cognition disorders, dementia, drug effects, epidemiology, etiology, executive function, female, fibric acids, france, genetics, humans, hydroxymethylglutarylcoa reductase inhibitors, lipid, lowering, male, memory, neuropsychological tests, pharmacology, psychomotor performance, sex factors, therapeutic use

Countries of Study


Types of Study

Cohort Study

Type of Outcomes




Type of Interventions

Risk Factor Modification

Risk Factor Modifications

General population health promotion